Practice-Changing Use Of The 21-Gene Oncotype Dx Breast Recurrence Score Test In Latin American Hospitals.

Henry Leonidas Gomez,Juan Enrique Bargallo-Rocha, Roberto Jorge Billinghurst,Aníbal Roberto Núñez de Pierro,Federico Andrés Coló, Lisandro Luis Benitez Gil,Carola Allemand, Ignacio Leonardo McLean, Mauricio Lema-Medina, Fernando Herazo-Maya, Francisco Jose Terrier,Raquel Gerson Cwilich, Mauricio León Rivera,Silvia Gabriela Falcon, Roberto Eduardo Castaño,Sergio Cordeiro Oliveira,Debbie M Jakubowski,Calvin Y. Chao

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 2|浏览23

暂无评分

摘要

e12539Background: The 21-gene test is clinically validated to predict chemotherapy (CT) benefit in node-negative (N0) and node-positive (up to 3 axillary nodes, N+) HR+, HER2− early-stage breast ca...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要